Innate Pharma’s (IPHA) “Buy” Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Innate Pharma (NASDAQ:IPHA) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $8.00 price target on the stock.

Other equities analysts have also issued research reports about the company. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down previously from $10.00) on shares of Innate Pharma in a research note on Thursday, September 18th. HC Wainwright set a $5.00 price objective on Innate Pharma and gave the stock a “buy” rating in a report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Innate Pharma in a research note on Wednesday, October 8th. Finally, Leerink Partnrs cut shares of Innate Pharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $5.00.

Innate Pharma Stock Performance

IPHA stock opened at $1.97 on Wednesday. The company has a 50 day moving average price of $2.03 and a 200 day moving average price of $2.04. Innate Pharma has a fifty-two week low of $1.29 and a fifty-two week high of $3.51.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.